Inflammatory bowel disease and risk of coronary heart disease

Trends in Cardiovascular Medicine

Volumn 25, Issue 8, 2015, Pages 699-704

  Rungoe, Christine ^a   Nyboe Andersen, Nynne ^a   Jess, Tine ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ARTERIAL STIFFNESS; BODY MASS; CARDIOVASCULAR RISK; CROHN DISEASE; DIARRHEA; DISEASE ASSOCIATION; FEVER; HEART INFARCTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOKING; ULCERATIVE COLITIS; WEIGHT REDUCTION; ADULT; AGE DISTRIBUTION; AGED; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 84945496649     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.03.010     Document Type: Review

References (50)

1. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
2. Cohn J.N. Prevention of cardiovascular disease. Trends Cardiovasc Med 2014, http://dx.doi.org/10.1016/j.tcm.2014.12.005.
3. Matsuura E., Atzeni F., Sarzi-Puttini P., Turiel M., Lopez L.R., Nurmohamed M.T. Is atherosclerosis an autoimmune disease?. BMC Med 2014, 12:47.
4. Libby P., Lichtman A.H., Hansson G.K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013, 38:1092-1104.
5. Prasad M., Hermann J., Gabriel S.E., Weyand C.M., Mulvagh S., Mankad R., et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2014, 12(3):168-176.
6. Conrad K., Roggenbuck D., Laass M.W. Diagnosis and classification of ulcerative colitis. Autoimmun Rev 2014, 13:463-466.
7. Laass M.W., Roggenbuck D., Conrad K. Diagnosis and classification of Crohn[U+05F3]s disease. Autoimmun Rev 2014, 13:467-471.
8. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004, 99:1371-1385.
9. Baumgart D.C., Sandborn W.J. Crohn[U+05F3]s disease. Lancet 2012, 380:1590-1605.
10. Danese S., Fiocchi C. Ulcerative colitis. N Engl J Med 2011, 365:1713-1725.
11. Bernstein C.N., Wajda A., Svenson L.W., MacKenzie A., Koehoorn M., Jackson M., et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006, 101:1559-1568.
12. Loftus C.G., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Tremaine W.J., Melton L.J., et al. Update on the incidence and prevalence of Crohn[U+05F3]s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13:254-261.
13. Burisch J., Jess T., Martinato M., Lakatos P.L. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013, 7:322-337.
14. Ng S.C. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol 2014, 28:363-372.
15. Larsen S., Bendtzen K., Nielsen O.H. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010, 42:97-114.
16. Nguyen G.C., Bernstein C.N., Bitton A., Chan A.K., Griffiths A.M., Leontiadis G.I., et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014, 146:835-848.
17. Bernstein C.N., Wajda A., Blanchard J.F. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008, 6:41-45.
18. Ha C., Magowan S., Accortt N.A., Chen J., Stone C.D. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009, 104:1445-1451.
19. Yarur A.J., Deshpande A.R., Pechman D.M., Tamariz L., Abreu M.T., Sussman D.A. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011, 106:741-747.
20. Sridhar A.R., Parasa S., Navaneethan U., Crowell M.D., Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis 2011, 5:287-294.
21. Osterman M.T., Yang Y.X., Brensinger C., Forde K.A., Lichtenstein G.R., Lewis J.D. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn[U+05F3]s disease. Clin Gastroenterol Hepatol 2011, 9:875-880.
22. Rungoe C., Basit S., Ranthe M.F., Wohlfahrt J., Langholz E., Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013, 62:689-694.
23. Kristensen S.L., Ahlehoff O., Lindhardsen J., Erichsen R., Jensen G.V., Torp-Pedersen C., et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death-a Danish nationwide cohort study. PLoS One 2013, 8:e56944.
24. Zoller B., Li X., Sundquist J., Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One 2012, 7:e33442.
25. Singh S., Singh H., Loftus E.V., Pardi D.S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014, 12:382-393.
26. Fumery M., Xiaocang C., Dauchet L., Gower-Rousseau C., Peyrin-Biroulet L., Colombel J.F. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 2014, 8:469-479.
27. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
28. Singh S., Kullo I.J., Pardi D.S., Loftus E.V. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 2015, 12:26-35.
29. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
30. Danese S., Motte Cd C.L., Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004, 99:938-945.
31. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384.
32. Lehmann F.S., Burri E., Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol 2015, 8:23-36.
33. Jensen L.J., Pedersen S., Bjerre M., Mogelvang R., Jensen J.S., Flyvbjerg A. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol 2010, 23:123-129.
34. Gandhi S., Narula N., Marshall J.K., Farkouh M. Are patients with inflammatory bowel disease at increased risk of coronary artery disease?. Am J Med 2012, 125:956-962.
35. Haapamaki J., Roine R.P., Turunen U., Farkkila M.A., Arkkila P.E. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 2011, 5:41-47.
36. Tsai M.S., Lin C.L., Chen H.P., Lee P.H., Sung F.C., Kao C.H. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. Inflamm Bowel Dis 2014, 20:502-507.
37. Geerling B.J., Badart-Smook A., Stockbrugger R.W., Brummer R.J. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000, 54:514-521.
38. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004, 18:481-496.
39. Stone N.J., Robinson J.G., Lichtenstein A.H., Goff D.C., Lloyd-Jones D.M., Smith S.C., et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014, 160:339-343.
40. Vyroubal P., Chiarla C., Giovannini I., Hyspler R., Ticha A., Hrnciarikova D., et al. Hypocholesterolemia in clinically serious conditions-review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008, 152:181-189.
41. Robertson J., Peters M.J., McInnes I.B., Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013, 9:513-523.
42. Sappati Biyyani R.S., Fahmy N.M., Baum E., Nelson K.M., King J.F. Inflammatory bowel disease and coronary artery disease. Indian J Gastroenterol 2009, 28:28-30.
43. Aggarwal A., Atreja A., Kapadia S., Lopez R., Achkar J.P. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm Bowel Dis 2014, 20:1593-1601.
44. Theocharidou E., Gossios T.D., Giouleme O., Athyros V.G., Karagiannis A. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology 2014, 65:284-293.
45. Fan F., Galvin A., Fang L., White D.A., Moore X.L., Sparrow M., et al. Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) 2014, 11:29.
46. Zanoli L., Cannavo M., Rastelli S., Di P.L., Monte I., Di G.M., et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens 2012, 30:1775-1781.
47. Desreumaux P., Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 2006, 24:2-9.
48. Zanoli L., Rastelli S., Inserra G., Lentini P., Valvo E., Calcagno E., et al. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs. Atherosclerosis 2014, 234:346-351.
49. Dixon W.G., Symmons D.P. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007, 66:1132-1136.
50. Greenberg J.D., Kremer J.M., Curtis J.R., Hochberg M.C., Reed G., Tsao P., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582.